Patients with hypertrophic cardiomyopathy (HCM) exhibit a variable phenotype with ventricular hypertrophy as the cardinal manifestation and left ventricular (LV) outflow tract obstruction (LVOTO) as a key pathophysiologic determinant. Patients with severe LVOTO usually present with exertional dyspnea, exertional syncope, and heart failure symptoms, while successful relief of LVOTO by pharmacological or invasive interventions leads to a dramatic improvement in clinical status. Proper management of obstructive HCM remains challenging and poses numerous clinical dilemmas. Since the development of surgical myectomy over half a century ago, progress in the management of LVOTO in HCM has paralleled technological advances in genetic testing, cardiac imaging, arrhythmic prophylaxis, cardiac surgery and interventional cardiology. These changes have been incorporated in dedicated scientific guidelines on both sides of the Atlantic. However, either the 2011 American guidelines or the 2014 European guidelines remain largely based on expert consensus for lack of recommendations with level of evidence A regarding any of the treatment options commonly employed in HCM. Consequently, management of obstructive HCM patients remains largely subjective and dependent on clinical judgment, local expertise, and patient preference. Following the trend that has emerged for other cardiac diseases amenable to invasive interventions, adequate evaluation and management of obstruction in HCM today requires a multidisciplinary team capable of optimizing referral, choosing the best available options, minimizing complications and ensuring state-of-the-art results. The concept of an HCM Heart Team is coming of age. This review aims to provide an update of available pharmacologic and invasive options for the management of LVOTO in HCM, either in adulthood or in childhood, highlighting areas for multidisciplinary integration and future development.

Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020. towards the HCM heart team / Pelliccia, F.; Alfieri, O.; Calabro, P.; Cecchi, F.; Ferrazzi, P.; Gragnano, F.; Kaski, J. P.; Limongelli, G.; Maron, M.; Rapezzi, C.; Seggewiss, H.; Yacoub, M. H.; Olivotto, I.. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - 304:(2020), pp. 86-92. [10.1016/j.ijcard.2020.01.021]

Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020. towards the HCM heart team

Pelliccia F.
;
Cecchi F.;Limongelli G.;
2020

Abstract

Patients with hypertrophic cardiomyopathy (HCM) exhibit a variable phenotype with ventricular hypertrophy as the cardinal manifestation and left ventricular (LV) outflow tract obstruction (LVOTO) as a key pathophysiologic determinant. Patients with severe LVOTO usually present with exertional dyspnea, exertional syncope, and heart failure symptoms, while successful relief of LVOTO by pharmacological or invasive interventions leads to a dramatic improvement in clinical status. Proper management of obstructive HCM remains challenging and poses numerous clinical dilemmas. Since the development of surgical myectomy over half a century ago, progress in the management of LVOTO in HCM has paralleled technological advances in genetic testing, cardiac imaging, arrhythmic prophylaxis, cardiac surgery and interventional cardiology. These changes have been incorporated in dedicated scientific guidelines on both sides of the Atlantic. However, either the 2011 American guidelines or the 2014 European guidelines remain largely based on expert consensus for lack of recommendations with level of evidence A regarding any of the treatment options commonly employed in HCM. Consequently, management of obstructive HCM patients remains largely subjective and dependent on clinical judgment, local expertise, and patient preference. Following the trend that has emerged for other cardiac diseases amenable to invasive interventions, adequate evaluation and management of obstruction in HCM today requires a multidisciplinary team capable of optimizing referral, choosing the best available options, minimizing complications and ensuring state-of-the-art results. The concept of an HCM Heart Team is coming of age. This review aims to provide an update of available pharmacologic and invasive options for the management of LVOTO in HCM, either in adulthood or in childhood, highlighting areas for multidisciplinary integration and future development.
2020
alcohol septal ablation; cradient; hypertrophic cardiomyopathy; left ventricular outflow tract; myectomy; obstruction
01 Pubblicazione su rivista::01a Articolo in rivista
Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020. towards the HCM heart team / Pelliccia, F.; Alfieri, O.; Calabro, P.; Cecchi, F.; Ferrazzi, P.; Gragnano, F.; Kaski, J. P.; Limongelli, G.; Maron, M.; Rapezzi, C.; Seggewiss, H.; Yacoub, M. H.; Olivotto, I.. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - 304:(2020), pp. 86-92. [10.1016/j.ijcard.2020.01.021]
File allegati a questo prodotto
File Dimensione Formato  
Pelliccia_Multidisciplinary_2020.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 757.32 kB
Formato Adobe PDF
757.32 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1440575
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 32
social impact